Novo Nordisk A/S (NYSE:NVO)
$ 136.27 0.7 (0.52%) Market Cap: 607.04 Bil Enterprise Value: 609.77 Bil PE Ratio: 47.15 PB Ratio: 42.45 GF Score: 92/100

Novo Nordisk A/S Investor and Analyst Event at ADA 2019 Transcript

Jun 10, 2019 / 02:00AM GMT
Release Date Price: $25.61 (+3.81%)
Karsten Munk Knudsen;S;Executive VP;CFO
Novo Nordisk A

/-&

Good evening. What a fantastic amount of energy, right, on a Sunday night on the West Coast. Jet lag or what, I'm not sure -- the opposite.

So welcome to the Novo Nordisk investor event in connection with the ADA 2019 San Francisco. We are here, our whole team, and it's a pleasure to introduce -- first of all, my name is Karsten Knudsen. I'm the CFO of Novo Nordisk. And I have a fantastic team on board here. If we start from the right-hand side, Robin Evers, Head of Safety, Medical Affairs and Regulatory Affairs. So any question on FDA or EMA and all the intricacies around that, Robin is your man. Then we have Stephen Gough, Chief Medical Officer. Stephen knows everything, right?

Stephen Gough;S;Global Chief Medical Officer;Karsten Munk Knudsen;S;Executive VP;CFO<
Novo Nordisk A;Novo Nordisk A

/-

Not everything, just medical.

- /-&

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot